Cyclooxygenase-2 deficiency exacerbates bleomycin-induced lung dysfunction but not fibrosis

American Journal of Respiratory Cell and Molecular Biology

Volumn 37, Issue 3, 2007, Pages 300-308

  Card, Jeffrey W ^b   Voltz, James W ^b   Carey, Michelle A ^b   Bradbury, J Alyce ^b   DeGraff, Laura M ^b   Lih, Fred B ^b   Bonner, James C ^b   Morgan, Daniel L ^b   Flake, Gordon P ^b   Zeldin, Darryl C ^a  

^a NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^b NONE

Author keywords

Cyclooxygenase; Fibrosis; Prostaglandin; Respiratory mechanics; Transgenic

Indexed keywords

BLEOMYCIN; COLLAGEN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; PEPTIDOLEUKOTRIENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING MECHANICS; CLARA CELL; CONTROLLED STUDY; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME DEFICIENCY; HISTOPATHOLOGY; LUNG COMPLIANCE; LUNG FIBROSIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RESPIRATORY FAILURE;

ANIMALS; BLEOMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; EICOSANOIDS; FEMALE; GENE EXPRESSION; HUMANS; LUNG; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PULMONARY FIBROSIS; RECOMBINANT PROTEINS; RESPIRATORY MECHANICS;

MUS;

EID: 35948979208     PISSN: 10441549     EISSN: None     Source Type: Journal    
DOI: 10.1165/rcmb.2007-0057OC     Document Type: Article

References (28)

1. Keane MP, Strieter RM, Belperio JA. Mechanisms and mediators of pulmonary fibrosis. Crit Rev Immunol 2005;25:429-463.
2. Charbeneau RP, Peters-Golden M. Eicosanoids: mediators and therapeutic targets in fibrotic lung disease. Clin Sci (Lond) 2005;108:479-491.
3. Keerthisingam CB, Jenkins RG, Harrison NK, Hernandez-Rodriguez NA, Booth H, Laurent GJ, Hart SL, Foster ML, McAnulty RJ. Cyclooxygenase-2 deficiency results in a loss of the anti-proliferative response to transforming growth factor-beta in human fibrotic lung fibroblasts and promotes bleomycin-induced pulmonary fibrosis in mice. Am J Pathol 2001;158:1411-1422.
4. Wilborn J, Crofford LJ, Burdick MD, Kunkel SL, Strieter RM, Peters-Golden M. Cultured lung fibroblasts isolated from patients with idiopathic pulmonary fibrosis have a diminished capacity to synthesize prostaglandin E2 and to express cyclooxygenase-2. J Clin Invest 1995;95:1861-1868.
5. Bonner JC, Rice AB, Ingram JL, Moomaw CR, Nyska A, Bradbury A, Sessoms AR, Chulada PC, Morgan DL, Zeldin DC, et al. Susceptibility of cyclooxygenase-2-deficient mice to pulmonary fibrogenesis. Am J Pathol 2002;161:459-470.
6. Lovgren AK, Jania LA, Hartney JM, Parsons KK, Audoly LP, Fitzgerald GA, Tilley SL, Roller BH. COX-2-derived prostacyclin protects against bleomycin-induced pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2006;291:L144-L156.
7. Hodges RJ, Jenkins RG, Wheeler-Jones CP, Copeman DM, Bottoms SE, Bellingan GJ, Nanthakumar CB, Laurent GJ, Hart SL, Foster ML, et al. Severity of lung injury in cyclooxygenase-2-deficient mice is dependent on reduced prostaglandin E(2) production. Am J Pathol 2004;165:1663-1676.
8. Card JW, Carey MA, Bradbury JA, Graves JP, Lih FB, Moorman MP, Morgan DL, Degraff LM, Zhao Y, Foley JF, et al. Cyclooxygenase-1 overexpression decreases Basal airway responsiveness but not allergic inflammation. J Immunol 2006;177:4785-4793.
9. Card JW, Carey MA, Bradbury JA, DeGraff LM, Morgan DL, Moorman MP, Flake GP, Zeldin DC. Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation. J Immunol 2006;177:621-630.
10. Salazar E, Knowles JH. An analysis of pressure-volume characteristics of the lungs. J Appl Physiol 1964;19:97-104.
11. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470.
12. Sansores RH, Ramirez-Venegas A, Perez-Padilla R, Montano M, Ramos C, Becerril C, Gaxiola M, Pare P, Selman M. Correlation between pulmonary fibrosis and the lung pressure-volume curve. Lung 1996;174:315-323.
13. Goldstein RH, Lucey EC, Franzblau C, Snider GL. Failure of mechanical properties to parallel changes in lung connective tissue composition in bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis 1979;120:67-73.
14. Bergaya S, Meneton P, Bloch-Faure M, Mathieu E, Alhenc-Gelas F, Levy BI, Boulanger CM. Decreased flow-dependent dilation in carotid arteries of tissue kallikrein-knockout mice. Circ Res 2001; 88:593-599.
15. Li G, Siddiqui J, Hendry M, Akiyama J, Edmondson J, Brown C, Allen L, Levitt S, Poulain F, Hawgood S. Surfactant protein-A-deficient mice display an exaggerated early inflammatory response to a beta-resistant strain of influenza A virus. Am J Respir Cell Mol Biol 2002; 26:277-282.
16. Zhou Y, Chen Y, Dirksen WP, Morris M, Periasamy M. AT1b receptor predominantly mediates contractions in major mouse blood vessels. Circ Res 2003;93:1089-1094.
17. Blednov YA, Stoffel M, Alva H, Harris RA. A pervasive mechanism for analgesia: activation of GIRK2 channels. Proc Natl Acad Sci USA 2003;100:277-282.
18. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med 2006;174:803-809.
19. Jegal Y, Kim DS, Shim TS, Lim CM, Do Lee S, Koh Y, Kim WS, Kim WD, Lee JS, Travis WD, et al. Physiology is a stronger predictor of survival than pathology in fibrotic interstitial pneumonia. Am J Respir Crit Care Med 2005;171:639-644.
20. Azoulay E, Herigault S, Levame M, Brochard L, Schlemmer B, Harf A, Delclaux C. Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Crit Care Med 2003;31:1442-1448.
21. Gunther A, Lubke N, Ermert M, Schermuly RT, Weissmann N, Breithecker A, Markart P, Ruppert C, Quanz K, Ermert L, et al. Prevention of bleomycin-induced lung fibrosis by aerosolization of heparin or urokinase in rabbits. Am J Respir Crit Care Med 2003; 168:1358-1365.
22. Beller TC, Friend DS, Maekawa A, Lam BK, Austen KF, Kanaoka Y. Cysteinyl leukotriene 1 receptor controls the severity of chronic pulmonary inflammation and fibrosis. Proc Natl Acad Sci USA 2004; 101:3047-3052.
23. Peters-Golden M, Bailie M, Marshall T, Wilke C, Phan SH, Toews GB, Moore BB. Protection from pulmonary fibrosis in leukotriene-deficient mice. Am J Respir Crit Care Med 2002;165:229-235.
24. Failla M, Genovese T, Mazzon E, Gili E, Muia C, Sortino M, Crimi N, Caputi AP, Cuzzocrea S, Vancheri C. Pharmacological inhibition of leukotrienes in an animal model of bleomycin-induced acute lung injury. Respir Res 2006;7:137.
25. Ogletree ML, Snapper JR, Brigham KL. Direct and indirect effects of leukotriene D4 on the lungs of unanesthetized sheep. Respiration (Herrlisheim) 1987;51:256-265.
26. Drazen JM, Venugopalan CS, Austen KF, Brion F, Corey EJ. Effects of leukotriene E on pulmonary mechanics in the guinea pig. Am Rev Respir Dis 1982;125:290-294.
27. Krell RD, Williams JC, Giles RE. Pharmacology of aerosol leukotriene C4- and D4-induced alteration of pulmonary mechanics in anesthetized cynomolgus monkeys. Prostaglandins 1986;32:769-780.
28. Folco G, Murphy RC. Eicosanoid transcellular biosynthesis: from cell-cell interactions to in vivo tissue responses. Pharmacol Rev 2006;58:375-388.